Accuray and RaySearch Announce Long-Term Collaboration Agreement Regarding the RayCare® Oncology Information System

SUNNYVALE, Calif., and STOCKHOLM, Sweden July 13, 2015 -- Accuray Incorporated
(Nasdaq: ARAY) and RaySearch Laboratories AB (publ) (NASDAQ OMX Stockholm: RAY
B) announced today they have signed a long-term collaboration agreement which
will allow Accuray to co-market and offer the RayCare®oncology information
system (OIS) which is currently in development at RaySearch. Under the contract,
Accuray will have the opportunity to offer RayCare®in several designated major
radiation therapy markets, making available a fully-integrated solution with the
TomoTherapy®and CyberKnife®System product portfolios. RaySearch, known for its
innovative, advanced and user-friendly treatment planning software, RayStation®,
and Accuray, recognized for its innovative tumor treatments, are partnering to
provide the radiation oncology community with a creative approach for delivering
and managing precise radiation therapy.
RayCare®is a next generation OIS developed from the ground up by RaySearch to
support the complex logistical challenges in modern large-scale radiation
therapy centers. RayCare®integrates the high performance radiation therapy
algorithms available in RayStation®and adds advanced features for clinical
resource optimization, workflow automation and adaptive radiation therapy. The
system is expected to be released in 2017.
“In today’s complex healthcare environment it is becoming increasingly important
to deliver clinical excellence and successful outcomes for cancer patients
through radiation treatment options, which are both effective and efficient,”
said Joshua H. Levine, president and chief executive officer of Accuray. “Our
goal in partnering with RaySearch is to provide solutions that will enhance the
integration of the TomoTherapy and CyberKnife technologies with our customers’
oncology department workflow, enabling them to more easily manage the large
volumes of clinical data and to streamline their patients’ radiation
treatments.”
“The RaySearch and Accuray collaboration agreement brings together two companies
dedicated to providing clinicians with innovative solutions which result in more
effective radiation therapy for cancer patients,” said Johan Löf, president and
chief executive officer of RaySearch Laboratories AB (publ). “We believe
RayCare®has the potential to set a new standard for oncology information systems
and will enable cancer centers to optimize their workflow and use of resources
to maximize the level of care they provide to their patients.”
About the Cyberknife and TomoTherapy Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series treatment solutions
cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series
enables precise, high-quality, high-dose distributions to be confidently
delivered to the patient with extreme accuracy over a minimum number of
treatments, reducing side effects and preserving patients' quality of life. The
CyberKnife System is the only robotic full-body radiosurgery system available
today. The TomoTherapy H Series efficiently enables physicians to customize
treatment plans for the entire range of radiation therapy patients and disease
types. Its innovative design enables treatment plans to be delivered with
integrated, daily CT image guidance, enhancing accuracy and delivering highly
precise, intensity-modulated radiation for optimal sparing of healthy tissue and
critical structures.
Further information on Accuray, the CyberKnife and TomoTherapy Systems is
available at www.accuray.com.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that
develops, manufactures and sells precise, innovative tumor treatment solutions
that set the standard of care with the aim of helping patients live longer,
better lives. The company's leading-edge technologies deliver the full range of
radiation therapy and radiosurgery treatments.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact
are forward-looking statements and are subject to the “safe harbor” provisions
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release relate, but are not limited, to future growth,
market success, adoption of our new products, clinical benefits of our
technologies, patient outcomes and Accuray’s leadership position in radiation
oncology innovation and technologies. Forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ materially
from expectations, including but not limited to the risks detailed under the
heading “Risk Factors” in the company’s report on Form 10-K, filed on August 29,
2014, the company’s reports on Form 10-Q, filed on November 7, 2014, February 6,
2015 and May 7, 2015, and the company’s other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and
are based on information available to Accuray at the time those statements are
made and/or management’s good faith belief as of that time with respect to
future events. The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in assumptions or
changes in other factors affecting forward-looking information, except to the
extent required by applicable securities laws. Accordingly, investors should not
put undue reliance on any forward-looking statements.
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops
advanced software solutions for improved radiation therapy of cancer. RaySearch
markets the RayStation®treatment planning system to clinics all over the world.
In addition, RaySearch’s products are distributed through licensing agreements
with leading medical technology companies. RaySearch’s software solutions are
used by over 2,500 clinics in more than 65 countries.

RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in
Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX
Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information please contact:

Accuray
Investors:
Chris Dailey
Investor Relations, EVC Group
+1 (646) 445-4801
Cdailey@evcgroup.com
Media:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
RaySearch Laboratories AB (publ)
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
johan.lof@raysearchlabs.com